Lupus & antiphospholipid syndrome
Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study
Authors' conclusion
In SLE patients, exposure to SGLT2 inhibitors was associated with improved kidney function and a reduced risk of developing adverse kidney outcomes.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients in the Clalit Health Services SLE registry, a national cohort of 4354 SLE patientspropensity-score matched
- Participants
- 260 vs 413
- Exposure
- SGLT2 inhibitor users vs non-users
- SGLT2 inhibitor usersn = 260
- Non-usersn = 413reference
- Outcome
- eGFR
- Follow-up
- 24 months
Methodological detailstwo-step propensity-score matched, national registry (CHS-SLE registry), real-world
- Two-step propensity-score matched
- National registry (CHS-SLE registry)
- Real-world
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Rapid decline in estimated glomerular filtration rate (eGFR) · 24 months
- Use of SGLT2 inhibitors associated with reduced risk of rapid decline in eGFR
- HR 0.74, 95 % CI 0.59-0.92, p = 0.01
Composite of rapid eGFR decline, ≥30 % eGFR decline and new-onset end-stage kidney disease (ESKD) · 24 months
- Use of SGLT2 inhibitors associated with reduced risk of the composite outcome
- HR 0.72, 95 % CI 0.53-0.97, p = 0.03
Original publication
Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study. Semin Arthritis Rheum. Published 8 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →